Global Allergy Diagnostics and Therapeutics Market Size/Share Worth USD 78,036.1 Million by 2033 at a 8.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
18 nov. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Allergy Diagnostics and Therapeutics Market Size, Trends and Insights By Product...
Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions
07 nov. 2022 07h00 HE
|
InCarda Therapeutics, Inc.
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...
InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth
04 oct. 2022 07h00 HE
|
InCarda Therapeutics, Inc.
Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience Grace E, Colón, Ph.D., Stepping Aside Following Nearly Ten Years as...
InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial Fibrillation
23 juin 2021 08h05 HE
|
InCarda Therapeutics, Inc.
Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Data Expected 2H 2022 ...
InCarda Therapeutics Provides Corporate Update Highlighting New Phase 2 Data for InRhythm™ Program, Plans for Pivotal Phase 3 Study and Expansion of Senior Management Team
09 juin 2021 08h05 HE
|
InCarda Therapeutics, Inc.
Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in...
InCarda Therapeutics Announces Enrollment of First U.S. Patient in Phase 2 INSTANT Trial of InRhythm™ for Treatment of Atrial Fibrillation
19 janv. 2021 08h05 HE
|
InCarda Therapeutics, Inc.
SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
InCarda Therapeutics Raises $30 Million Through First Close of Series C Equity Financing
21 oct. 2020 08h05 HE
|
InCarda Therapeutics, Inc.
Proceeds to Support Ongoing Clinical Development of InRhythm™, A First-of-its-Kind Inhaled Antiarrhythmic for Treatment of Paroxysmal Atrial Fibrillation (PAF) Positive Phase 2 Data Scheduled for...
InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones
08 nov. 2018 08h05 HE
|
InCarda Therapeutics, Inc.
Oversubscribed $42 Million Series B Financing Provides Significant Runway to Support Continued Advancement of Innovative Inhaled Cardiovascular Therapy First Patients Dosed in Phase 2 Clinical Trial...
Nu-Med Plus Announces Investigational Study of Stored Blood as a New Path for Their NO Devices
10 mai 2016 08h00 HE
|
Nu-Med Plus, Inc.
SALT LAKE CITY, UT--(Marketwired - May 10, 2016) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announces they are embarking on a new investigational study applying...
Nu-Med Plus Inc. Files Utility Patent for Low Cost Inhaled Nitric Oxide Technology
26 janv. 2016 08h00 HE
|
Nu-Med Plus, Inc.
SALT LAKE CITY, UT--(Marketwired - January 26, 2016) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device company which explores and develops medical applications of new technologies in the...